drugset / Trial / NCT01603355

Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis

NCT01603355

Phase 1/2 Terminated 3 enrolled Eric B. Suhler Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The investigators are doing this research study to see if tocilizumab (Actemra) is safe and effective when used for severe or refractory non-infectious uveitis. Uveitis is an inflammation of the eye that is caused by the body's immune system reacting against the eye tissues.

Timeline

Start
2013-11
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous
Subject Tocilizumab Monoclonal antibody 10 mg/kg Intravenous